Based on all of this, when performing LT, protection against the negative effects of BD may be provided by treatment adopting a strategy based on inhibiting the action of endogenous IL-1β, since such a strategy has been shown to be beneficial in liver grafts from DBDs both in the presence and in the absence of steatosis. The gene discussed is IL1B; the disease is steatosis.